Literature DB >> 1576065

Stereoselective disposition of flurbiprofen in normal volunteers.

M P Knadler1, D C Brater, S D Hall.   

Abstract

1. The concentrations of the R- and S-enantiomers of flurbiprofen and its metabolites were measured in plasma and urine following the oral administration of 50 mg racemic flurbiprofen to six normal volunteers. 2. The AUC and half-life of the R-enantiomer were significantly lower than the corresponding S-enantiomer values reflecting the greater clearance of R-flurbiprofen (20.42 +/- 4.71 vs 16.12 +/- 3.60 ml min-1). 3. Ex vivo protein binding studies indicated that the percent unbound of R-flurbiprofen was (not significantly) greater than that of the S-enantiomer (0.055 +/- 0.008 vs 0.049 +/- 0.009) and the corresponding unbound clearances did not show enantioselectivity. 4. Both enantiomers were cleared primarily by metabolism to an acylglucuronide and 4'-hydroxyflurbiprofen. There was significant enantioselectivity (R greater than S) in the formation clearances of these metabolites which remained when unbound metabolite formation clearances were considered. 5. In conclusion, the disposition of the enantiomers of flurbiprofen exhibits enantioselectivity at the level of protein binding and metabolite formation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576065      PMCID: PMC1381325          DOI: 10.1111/j.1365-2125.1992.tb04054.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

Review 1.  Enantioselective aspects of drug action and disposition: therapeutic pitfalls.

Authors:  F Jamali; R Mehvar; F M Pasutto
Journal:  J Pharm Sci       Date:  1989-09       Impact factor: 3.534

2.  Variations in response to non-steroidal anti-inflammatory drugs.

Authors:  R O Day; P M Brooks
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

3.  Stereoselective plasma protein binding of ibuprofen enantiomers.

Authors:  A M Evans; R L Nation; L N Sansom; F Bochner; A A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs--1. In vitro studies of ibuprofen and flurbiprofen.

Authors:  R D Knihinicki; K M Williams; R O Day
Journal:  Biochem Pharmacol       Date:  1989-12-15       Impact factor: 5.858

5.  Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships.

Authors:  G J Szpunar; K S Albert; G G Bole; J N Dreyfus; G F Lockwood; J G Wagner
Journal:  Biopharm Drug Dispos       Date:  1987 May-Jun       Impact factor: 1.627

Review 6.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

7.  Stereoselective disposition of ibuprofen enantiomers in man.

Authors:  E J Lee; K Williams; R Day; G Graham; D Champion
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

8.  The warfarin-sulfinpyrazone interaction: stereochemical considerations.

Authors:  S Toon; L K Low; M Gibaldi; W F Trager; R A O'Reilly; C H Motley; D A Goulart
Journal:  Clin Pharmacol Ther       Date:  1986-01       Impact factor: 6.875

9.  Stereoselective inversion of (R)-fenoprofen to (S)-fenoprofen in humans.

Authors:  A Rubin; M P Knadler; P P Ho; L D Bechtol; R L Wolen
Journal:  J Pharm Sci       Date:  1985-01       Impact factor: 3.534

10.  Stereoselective pharmacokinetics of flurbiprofen in humans and rats.

Authors:  F Jamali; B W Berry; M R Tehrani; A S Russell
Journal:  J Pharm Sci       Date:  1988-08       Impact factor: 3.534

View more
  7 in total

1.  Stereoselective disposition of flurbiprofen in uraemic patients.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

2.  Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.

Authors:  N K Zgheib; R F Frye; T S Tracy; M Romkes; R A Branch
Journal:  Br J Clin Pharmacol       Date:  2006-10-19       Impact factor: 4.335

3.  The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis.

Authors:  P J Hayball; R L Nation; F Bochner; L N Sansom; M J Ahern; M D Smith
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

4.  Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers.

Authors:  G Geisslinger; J Lötsch; S Menzel; G Kobal; K Brune
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of flurbiprofen and its enantiomers.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

6.  Inhibition of endocannabinoid metabolism by the metabolites of ibuprofen and flurbiprofen.

Authors:  Jessica Karlsson; Christopher J Fowler
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

7.  Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans.

Authors:  Ikuko Yataba; Noboru Otsuka; Isao Matsushita; Miho Kamezawa; Ichimaro Yamada; Sigeru Sasaki; Kazuo Uebaba; Hideo Matsumoto; Yuichi Hoshino
Journal:  Eur J Clin Pharmacol       Date:  2015-10-06       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.